Aribio and AriBio LAB said on the 15th they will jointly attend the world's largest biotech event, the BIO International Convention (BIO USA), to be held in San Diego, the United States, starting on the 22nd.
The two companies will combine Aribio's Alzheimer's drug development capabilities with AriBio LAB's vaccine and immunology platform technologies to launch a group-level global business expansion strategy in earnest.
This appearance is the first major international event since establishing the global commercialization foundation for the Alzheimer's treatment AR1001. Aribio plans to use the occasion to expand global partnering for its subsequent central nervous system (CNS) pipeline and electroceutical technologies.
The core pipeline AR1005 is being developed as a treatment for dementia with Lewy bodies (DLB) and is currently in phase 2 at Severance Hospital. DLB is the second most common degenerative dementia after Alzheimer's, characterized by hallucinations, cognitive decline, and Parkinson's disease–like motor symptoms, and there is no fundamental treatment to date.
Another pipeline, GVD-01, is an electroceutical based on tactile vibration auditory stimulation (tVAS) and has completed an exploratory clinical trial in patients with early Alzheimer's disease. The company is pushing to expand indications to mild cognitive impairment (MCI), neuropsychiatric symptoms after stroke, and sleep disorders.
AriBio LAB is pursuing commercialization in vaccines and immunology based on its proprietary adjuvant platform "Lipopharm." It is currently conducting a phase 2 clinical trial for a shingles vaccine and is pushing to expand various vaccine and immunology pipelines using the Lipopharm platform. It is also seeking strategic collaboration with NK cell–based programs.
At this event, AriBio LAB will discuss co-development and out-licensing based on Lipopharm, while Aribio will focus on finding global partners for CNS therapeutics and electroceutical technologies. Furthermore, the two companies will discuss the potential to expand new immunology pipelines, including an Alzheimer's vaccine.
Their strategy is for Aribio to lead CNS new drug development and global clinical and commercialization activities, and for AriBio LAB to handle the vaccine and immunology platform and related pipelines, building a scalable biotech business model that spans both therapeutic and preventive areas.
Fred Kim, head of Aribio's U.S. office, said, "This BIO USA is an important stage to jointly present the two companies' next-generation growth strategies based on AR1001's global achievements," adding, "We will combine technological capabilities and business development expertise to expand global partnering opportunities."